Gilead Sciences, Inc. (GILD) Holdings Boosted by DeDora Capital Inc.

DeDora Capital Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 14,632 shares of the biopharmaceutical company’s stock after purchasing an additional 3,370 shares during the period. DeDora Capital Inc.’s holdings in Gilead Sciences were worth $951,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its position in shares of Gilead Sciences by 199,789.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after acquiring an additional 31,335,030 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of Gilead Sciences by 6.9% during the 3rd quarter. Macquarie Group Ltd. now owns 443,302 shares of the biopharmaceutical company’s stock worth $34,228,000 after purchasing an additional 28,450 shares in the last quarter. Glenmede Trust Co. NA increased its position in shares of Gilead Sciences by 48.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,009,192 shares of the biopharmaceutical company’s stock worth $77,919,000 after purchasing an additional 329,998 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Gilead Sciences by 27.6% during the 3rd quarter. Captrust Financial Advisors now owns 11,091 shares of the biopharmaceutical company’s stock worth $856,000 after purchasing an additional 2,400 shares in the last quarter. Finally, Koshinski Asset Management Inc. increased its position in shares of Gilead Sciences by 82.5% during the 3rd quarter. Koshinski Asset Management Inc. now owns 10,605 shares of the biopharmaceutical company’s stock worth $819,000 after purchasing an additional 4,793 shares in the last quarter. 80.20% of the stock is owned by institutional investors.

In related news, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $65.07, for a total transaction of $175,689.00. Following the transaction, the director now owns 57,560 shares of the company’s stock, valued at approximately $3,745,429.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gayle E. Wilson sold 19,068 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the transaction, the director now directly owns 143,567 shares in the company, valued at approximately $9,630,474.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,402 shares of company stock valued at $2,613,954. 0.20% of the stock is owned by corporate insiders.

GILD has been the subject of a number of recent analyst reports. Wells Fargo & Co cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $95.00 to $68.00 in a research report on Monday, February 11th. Citigroup restated a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a research report on Tuesday, February 5th. Oppenheimer upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective for the company in a research report on Thursday, January 3rd. Raymond James set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, December 20th. Finally, Mizuho restated a “buy” rating and issued a $88.00 price objective on shares of Gilead Sciences in a research report on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $82.00.

Shares of NASDAQ:GILD opened at $64.54 on Wednesday. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a quick ratio of 3.30, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. The company has a market cap of $83.46 billion, a PE ratio of 10.49, a price-to-earnings-growth ratio of 4.12 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the consensus estimate of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.63 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $2.52 annualized dividend and a dividend yield of 3.90%. Gilead Sciences’s payout ratio is currently 40.98%.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Holdings Boosted by DeDora Capital Inc.” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.com-unik.info/2019/04/17/gilead-sciences-inc-gild-holdings-boosted-by-dedora-capital-inc.html.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: Do stock splits help investors?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit